Tixagevimab-cilgavimab is the only nonvaccine drug currently authorized in the United States for the prevention of COVID-19 infection in individuals who are moderately to severely immunocompromised or unable to receive COVI.
Keywords: COVID-19; immunocompromised; monoclonal antibodies; tixagevimab–cilgavimab.